



## ASX Release

### TPI Enterprises Ltd (TPE) Receives Medicinal Cannabis Licences

29<sup>th</sup> September 2017

TPI Enterprises Ltd (ASX: TPE) is pleased to announce that the Office of Drug Control, Commonwealth Department of Health has granted the following licences which will come into effect on Monday 3rd October:

1. Medicinal Cannabis Licence
2. Cannabis Research Licence

The Cannabis Research Licence authorises TPE to research the cultivation of cannabis plants and produce cannabis or cannabis resin for research relating to medicinal cannabis.

The Medicinal Cannabis Licence authorises TPE to cultivate cannabis plants and produce cannabis or cannabis resin for medicinal purposes.

TPE is planning to add medicinal cannabis to its suite of controlled drugs.

#### Further Information:

Jarrold Ritchie  
Managing Director  
TPI Enterprises Ltd  
+61 3 9301 0800

Jaime Pinto  
Company Secretary  
TPI Enterprises Ltd  
+612 9210 7020

#### About TPI Enterprises Ltd

TPI Enterprises Ltd (ASX:TPE) is one of three licenced poppy processors in Australia, and the only Australian-owned company. It is one of eight processors worldwide producing Narcotic Raw Material for the international pharmaceutical industry. TPI Enterprises has developed an innovative, efficient and environmentally-sustainable extraction and purification manufacturing process which allows the company to deliver a highly competitive pricing platform. The company's strategy is to secure access to regulated downstream narcotics markets to leverage its reliable, cost-competitive upstream raw material capability.